Kanghong Pharma announces stock option exercise and investor event

Chengdu Kanghong Pharmaceutical Group (SZSE:002773) announced the commencement of the third exercise period for the reserved portion of its 2021 stock option incentive plan, approved on August 27, 2025. Two eligible incentive recipients can exercise 35,400 stock options at an exercise price of CNY 13.84 per share. The exercise period spans from September 11, 2025, to July 10, 2026. The company's board confirmed that the performance conditions for this exercise period have been met, including a 2024 net profit growth rate of not less than 10%, based on 2023 audited net profit excluding non-recurring gains and losses and incentive costs.

The total share capital will increase from 921,320,954 shares to 921,356,354 shares if all eligible options are exercised, with the funds raised supplementing the company's working capital. The exercise is not expected to significantly impact the company's equity structure or listing status.

Separately, Chengdu Kanghong Pharmaceutical Group will participate in the "Sichuan Province 2025 Investor Online Group Reception Day and Half-Year Report Performance Briefing" on September 12, 2025, from 14:00 to 17:00. Company executives will address questions regarding 2024 and 2025 half-year performance, corporate governance, development strategies, and other investor concerns.